Page last updated: 2024-11-06

floxuridine and Menopause

floxuridine has been researched along with Menopause in 2 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.

Research Excerpts

ExcerptRelevanceReference
"Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years."3.70Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hata, Y1
Takahashi, H1
Sasaki, F1
Ogita, M1
Uchino, J1
Yoshimoto, M1
Akasaka, Y1
Nakanishi, Y1
Sawada, Y1
Takatsuka, Y1
Katoh, T1
Tsumura, I1
Kobayakawa, K1
Kawahara, T1

Other Studies

2 other studies available for floxuridine and Menopause

ArticleYear
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
    Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin

2000
[Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Cyclophospha

1992